Breaking News

Aesica Adds Commercial Director Position

By Kristin Brooks | February 3, 2014

Muir to lead all three of the company’s service offerings

Ian Muir has been appointed to the newly created position of commercial managing director at Aesica, effective February 24th. Mr. Muir will be responsible for all three of the company’s service offerings in API manufacture, formulation development and formulated products, and will lead business expansion efforts into new growth markets including China and Japan. He will report to chief executive officer, Dr. Robert Hardy.
Aesica’s business development, sales and marketing, key account and product management teams will report to Mr. Muir, who will be based at the company’s headquarters in Newcastle, UK.
Mr. Muir has 20 years of experience in the pharma industry. Most recently he was responsible for the global provision of contract development and manufacturing services for oral dose forms at Catalent. He has gained significant commercial experience in contract manufacturing roles for large pharmaceutical companies in Europe, the U.S. and Australia, and has led R&D activities and commercial manufacturing operations.
Dr. Hardy said, “Ian brings strong commercial business knowledge and has proven experience of delivering growth and will play a pivotal role in driving further business growth for Aesica across API, formulation development and formulated products.”
  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • DCAT Week ’16 Session Highlights

    Kristin Brooks, Contract Pharma||March 24, 2016
    API and Dose CMO Market Trends and Supply Strategies

  • Talking Trends with Aesica

    Talking Trends with Aesica

    Tim Wright, editor||February 26, 2016
    Managing director Ian Muir fills us in on the latest at the CDMO